Top Page
Rhythm Biosciences Ltd.
(Sydney:RHY)
Rhythm Biosciences Ltd. (RHY) vs. iShares MSCI Australia ETF (EWA)
Rhythm Biosciences Ltd. Business Overview & Revenue Model
Rhythm Biosciences Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.19M | 3.19M | 1.69M | 3.10M | 2.43M | 1.11M |
| Gross Profit | 372.04K | 2.97M | -1.36M | 2.91M | -101.48K | 961.86K |
| EBITDA | -3.53M | -3.53M | -8.35M | -11.11M | -11.10M | -6.46M |
| Net Income | -3.83M | -3.83M | -6.86M | -8.22M | -8.79M | -6.61M |
Balance Sheet | ||||||
| Total Assets | 2.83M | 2.83M | 1.52M | 7.70M | 8.44M | 3.07M |
| Cash, Cash Equivalents and Short-Term Investments | 1.48M | 1.48M | 754.50K | 4.17M | 7.60M | 2.27M |
| Total Debt | 1.11M | 1.11M | 163.82K | 84.61K | 170.14K | 0.00 |
| Total Liabilities | 2.17M | 2.17M | 651.54K | 1.82M | 1.07M | 1.36M |
| Stockholders Equity | 659.89K | 659.89K | 867.17K | 5.87M | 7.37M | 1.71M |
Cash Flow | ||||||
| Free Cash Flow | -2.94M | -2.94M | -6.22M | -7.06M | -6.24M | -5.47M |
| Operating Cash Flow | -2.92M | -2.92M | -6.14M | -6.96M | -6.21M | -5.40M |
| Investing Cash Flow | -582.96K | -582.96K | -82.28K | -99.12K | -27.01K | -68.27K |
| Financing Cash Flow | 4.19M | 4.19M | 2.80M | 3.63M | 11.85M | 5.90M |
Rhythm Biosciences Ltd. Technical Analysis
Rhythm Biosciences Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | AU$28.91M | ― | -97.79% | ― | ― | 23.85% | |
| ― | AU$180.75M | ― | -111.23% | ― | 12.96% | 40.81% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | AU$82.91M | -4.04 | -36.16% | ― | 62.81% | 16.37% | |
| ― | AU$30.97M | -7.29 | -501.54% | ― | ― | 56.42% | |
| ― | AU$5.67M | ― | ― | ― | -56.35% | 42.80% | |
| ― | AU$48.57M | ― | -37.78% | ― | 2.33% | 12.50% |
Rhythm Biosciences Ltd. Corporate Events
Rhythm Biosciences Ltd announced the successful evaluation of its ColoSTAT® test, which demonstrates consistent performance in detecting colorectal cancer across various age groups and genders. The test shows promise for early onset cancer detection in patients under 50 years old, addressing a growing need in the healthcare industry. The company plans further studies to establish statistical significance and aims for commercial release following regulatory assessments.
Rhythm Biosciences Ltd has announced significant progress in its operations for the first quarter of FY26, highlighted by strategic distribution partnerships for its Genetype product and advancements in the commercial readiness of its ColoSTAT® kits. The company has also successfully raised $3.75 million in capital, indicating strong investor confidence. These developments position Rhythm Biosciences to achieve its strategic objectives for the year, with a focus on commercializing ColoSTAT® and expanding its product offerings.
Rhythm Biosciences Ltd. has released an investor roadshow presentation, highlighting ongoing investigations and developments within the company. While the presentation includes forward-looking statements, it emphasizes that these are subject to change due to various uncertainties. The release underscores the company’s commitment to advancing its diagnostic technologies, although it advises caution regarding the reliance on speculative projections.
Rhythm Biosciences Ltd. has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement confirms the company’s adherence to the ASX Corporate Governance Council’s principles, highlighting their commitment to maintaining high standards of corporate governance. This announcement underscores the company’s dedication to transparency and accountability, potentially strengthening its position in the biotechnology sector and reassuring stakeholders of its governance practices.
Rhythm Biosciences Ltd announced the issuance of 333,333 ordinary shares without disclosure under the Corporations Act, complying with relevant provisions and confirming no excluded information needs to be disclosed. This move aligns with the company’s focus on enhancing its operational capabilities and market positioning in the medical diagnostics industry, particularly in cancer detection and prevention.
Rhythm Biosciences Ltd. has announced the quotation of 333,333 ordinary fully paid securities on the Australian Securities Exchange (ASX) as part of a previously disclosed transaction. This move is expected to enhance the company’s financial flexibility and support its ongoing efforts in advancing its diagnostic technologies, potentially strengthening its position in the medical diagnostics market.
Rhythm Biosciences Ltd. announced a proposed issue of 333,333 ordinary fully paid securities, scheduled for September 18, 2025. This move is part of a placement or other type of issue, potentially enhancing the company’s capital structure and supporting its strategic initiatives in the biotechnology sector.
Rhythm Biosciences Ltd announced that its 2025 Annual General Meeting will be held on November 5, 2025, in Melbourne, with the closing date for director nominations set for September 17, 2025. This meeting is significant for the company’s governance and strategic direction, potentially impacting its operations and positioning in the cancer diagnostics industry.
Rhythm Biosciences Limited has released its financial report for the year ending June 30, 2025, highlighting its progress towards commercializing its ColoSTAT® product. This development positions the company to potentially impact the cancer diagnostics market by offering a reliable and cost-effective solution for early cancer detection, which could have significant implications for stakeholders and the industry.
Rhythm Biosciences Limited reported a significant improvement in its financial performance for the year ending June 2025, with other income from ordinary activities increasing by 91% and losses after tax decreasing by 44%. The incorporation of RHY GeneType Pty Ltd as a wholly-owned subsidiary marks a strategic expansion, potentially enhancing the company’s capabilities in genetic testing and diagnostics.
Rhythm Biosciences has entered a strategic co-marketing partnership with the Know Your Lemons Foundation to promote its geneTypeTM Breast Cancer Risk Assessment Test. This collaboration aims to enhance brand awareness and commercialize the test by integrating it into the Know Your Lemons mobile app, reaching a vast audience of women in the US and Australia. The partnership aligns with Breast Cancer Awareness Month, leveraging the global campaign to emphasize early detection and proactive health management, potentially impacting the company’s market position and stakeholder engagement.
Rhythm Biosciences Ltd has issued 38,321,133 ordinary shares without disclosure under the Corporations Act, in compliance with relevant legal provisions. The company’s ColoSTAT® Test-Kit, a blood-based test for colorectal cancer detection, and geneType™ platform for genetic risk assessment, position Rhythm Biosciences to address growing demand in preventative healthcare and precision medicine markets.
Rhythm Biosciences Ltd. announced the application for quotation of 38,321,133 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of previously announced transactions, potentially enhancing the company’s capital structure and market presence, which could have implications for its strategic growth and stakeholder value.
Rhythm Biosciences Ltd has completed the validation of its ColoSTAT® assay and submitted a request to include it in the ISO15189 accreditation scope, paving the way for its commercialization. The ColoSTAT® test, which has shown high sensitivity and negative predictive value for colorectal cancer detection, offers a non-invasive alternative to stool-based tests and could significantly impact early cancer detection and patient management.
Rhythm Biosciences Ltd. has issued a prospectus for the offer of new options, which are not open to the general public. These options are offered to invited placement investors, directors, and the lead manager as part of a capital raising initiative. The exercise price for these options is set at $0.20. This move is part of the company’s strategy to bolster its financial position and support its ongoing operations in the medical diagnostics field. The issuance of these options is expected to have implications for the company’s market positioning and could potentially influence its stakeholder relationships.
Rhythm Biosciences Ltd. has released an investor presentation outlining their current status and future plans. The presentation highlights that several matters are under investigation and subject to change, indicating a period of transition and potential growth for the company. Stakeholders are advised to be cautious about forward-looking statements due to inherent uncertainties.
Rhythm Biosciences Ltd. has announced a proposed issue of 38,321,133 ordinary fully paid securities, with the issue date set for August 22, 2025. This move is part of a strategic effort to raise capital, potentially enhancing the company’s operational capabilities and strengthening its market position in the biotechnology sector.
Rhythm Biosciences Ltd. announced a proposed issue of securities, planning to release a significant number of options and ordinary shares. This move is likely aimed at raising capital to support its ongoing projects and operational expansion. The issuance, scheduled for November 2025, could strengthen the company’s financial position, allowing it to further its research and development efforts in the diagnostic sector. This strategic financial maneuver may enhance Rhythm Biosciences’ market competitiveness and provide stakeholders with potential growth opportunities.
Rhythm Biosciences Ltd announced a successful capital raising of up to $3.75 million through a share placement at $0.09 per share, supported by both existing and new investors. The funds will be used to launch the ColoSTAT® colorectal cancer test, accelerate the commercialisation of the geneType™ portfolio, and support further R&D activities. This strategic move is expected to enhance the company’s market position and operational capabilities in the cancer diagnostics industry.
Rhythm Biosciences Ltd has requested a trading halt on its securities pending an announcement related to a capital raise. This halt will remain in place until the announcement is made or until normal trading resumes on August 18, 2025. The trading halt is a strategic move to manage the dissemination of information regarding the capital raise, which could have significant implications for the company’s financial strategy and stakeholder interests.
Rhythm Biosciences Ltd responded to an ASX price query, confirming no undisclosed information that could explain recent trading activity in its securities. The company affirmed compliance with listing rules and stated that its responses were authorized by its board. This announcement underscores Rhythm’s commitment to transparency and regulatory compliance, which is crucial for maintaining investor confidence and supporting its strategic goals in the competitive medical diagnostics industry.
Rhythm Biosciences Ltd has announced that its ColoSTAT® kits have achieved breakthrough clinical performance across all stages of colorectal cancer, from I to IV. The kits have transitioned to the final production validation stage, with high-quality kits received for internal testing. The consistent diagnostic performance across all cancer stages meets clinical requirements for use in symptomatic patient testing, with commercialization steps underway. The company plans to submit the ColoSTAT® for inclusion in its ISO15189 laboratory test portfolio, with a commercial launch expected later in 2025, pending regulatory approval.
Rhythm Biosciences Ltd. announced the cessation of 950,000 securities due to the lapse of conditional rights, as the conditions for these options were not met by the set deadlines. This development may impact the company’s capital structure and could influence investor perceptions, highlighting the challenges in meeting certain operational milestones.
Rhythm Biosciences Ltd. announced the issuance of 500,000 unquoted ordinary fully paid employee securities as part of an employee incentive scheme. This move is likely aimed at retaining and motivating staff, which could enhance the company’s operational capabilities and competitive positioning in the biotechnology sector.